Cargando…
Clinical impact of combination therapy with baricitinib, remdesivir, and dexamethasone in patients with severe COVID-19
BACKGROUND: Coronavirus disease 2019 (COVID-19) has spread worldwide and is also an important disease in Japan. Thus, the optimal treatment strategy for severe COVID-19 should be established urgently. The effects of combination treatment with baricitinib—a Janus kinase inhibitor, remdesivir, and dex...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Japanese Respiratory Society. Published by Elsevier B.V.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8352677/ https://www.ncbi.nlm.nih.gov/pubmed/34413006 http://dx.doi.org/10.1016/j.resinv.2021.07.004 |
_version_ | 1783736235382013952 |
---|---|
author | Izumo, Takehiro Kuse, Naoyuki Awano, Nobuyasu Tone, Mari Sakamoto, Keita Takada, Kohei Muto, Yutaka Fujimoto, Kazushi Saiki, Ayae Ito, Yu Matsumoto, Haruko Inomata, Minoru |
author_facet | Izumo, Takehiro Kuse, Naoyuki Awano, Nobuyasu Tone, Mari Sakamoto, Keita Takada, Kohei Muto, Yutaka Fujimoto, Kazushi Saiki, Ayae Ito, Yu Matsumoto, Haruko Inomata, Minoru |
author_sort | Izumo, Takehiro |
collection | PubMed |
description | BACKGROUND: Coronavirus disease 2019 (COVID-19) has spread worldwide and is also an important disease in Japan. Thus, the optimal treatment strategy for severe COVID-19 should be established urgently. The effects of combination treatment with baricitinib—a Janus kinase inhibitor, remdesivir, and dexamethasone (BRD) are unknown. METHODS: Patients who received combination therapy with BRD at the Japanese Red Cross Medical Center were enrolled in the study. All patients received baricitinib (≤14 d), remdesivir (≤10 d), and dexamethasone (≤10 d). The efficacy and adverse events were evaluated. RESULTS: In total, 44 patients with severe COVID-19 were enrolled in this study. The 28-d mortality rate was low at 2.3% (1/44 patients). The need for invasive mechanical ventilation was avoided in most patients (90%, 17/19 patients). Patients who received BRD therapy had a median hospitalization duration of 11 d, time to recovery of 9 d, duration of intensive care unit stay of 6 d, duration of invasive mechanical ventilation of 5 d, and duration of supplemental oxygen therapy of 5 d. Adverse events occurred in 15 patients (34%). Liver dysfunction, thrombosis, iliopsoas hematoma, renal dysfunction, ventilator-associated pneumonia, infective endocarditis, and herpes zoster occurred in 11%, 11%, 2%, 2%, 2%, 2%, and 2% of patients, respectively. CONCLUSIONS: Combination therapy with BRD was effective in treating severe COVID-19, and the incidence rate of adverse events was low. The results of the present study are encouraging; however, further randomized clinical studies are needed. |
format | Online Article Text |
id | pubmed-8352677 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | The Japanese Respiratory Society. Published by Elsevier B.V. |
record_format | MEDLINE/PubMed |
spelling | pubmed-83526772021-08-10 Clinical impact of combination therapy with baricitinib, remdesivir, and dexamethasone in patients with severe COVID-19 Izumo, Takehiro Kuse, Naoyuki Awano, Nobuyasu Tone, Mari Sakamoto, Keita Takada, Kohei Muto, Yutaka Fujimoto, Kazushi Saiki, Ayae Ito, Yu Matsumoto, Haruko Inomata, Minoru Respir Investig Original Article BACKGROUND: Coronavirus disease 2019 (COVID-19) has spread worldwide and is also an important disease in Japan. Thus, the optimal treatment strategy for severe COVID-19 should be established urgently. The effects of combination treatment with baricitinib—a Janus kinase inhibitor, remdesivir, and dexamethasone (BRD) are unknown. METHODS: Patients who received combination therapy with BRD at the Japanese Red Cross Medical Center were enrolled in the study. All patients received baricitinib (≤14 d), remdesivir (≤10 d), and dexamethasone (≤10 d). The efficacy and adverse events were evaluated. RESULTS: In total, 44 patients with severe COVID-19 were enrolled in this study. The 28-d mortality rate was low at 2.3% (1/44 patients). The need for invasive mechanical ventilation was avoided in most patients (90%, 17/19 patients). Patients who received BRD therapy had a median hospitalization duration of 11 d, time to recovery of 9 d, duration of intensive care unit stay of 6 d, duration of invasive mechanical ventilation of 5 d, and duration of supplemental oxygen therapy of 5 d. Adverse events occurred in 15 patients (34%). Liver dysfunction, thrombosis, iliopsoas hematoma, renal dysfunction, ventilator-associated pneumonia, infective endocarditis, and herpes zoster occurred in 11%, 11%, 2%, 2%, 2%, 2%, and 2% of patients, respectively. CONCLUSIONS: Combination therapy with BRD was effective in treating severe COVID-19, and the incidence rate of adverse events was low. The results of the present study are encouraging; however, further randomized clinical studies are needed. The Japanese Respiratory Society. Published by Elsevier B.V. 2021-11 2021-08-10 /pmc/articles/PMC8352677/ /pubmed/34413006 http://dx.doi.org/10.1016/j.resinv.2021.07.004 Text en © 2021 The Japanese Respiratory Society. Published by Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Original Article Izumo, Takehiro Kuse, Naoyuki Awano, Nobuyasu Tone, Mari Sakamoto, Keita Takada, Kohei Muto, Yutaka Fujimoto, Kazushi Saiki, Ayae Ito, Yu Matsumoto, Haruko Inomata, Minoru Clinical impact of combination therapy with baricitinib, remdesivir, and dexamethasone in patients with severe COVID-19 |
title | Clinical impact of combination therapy with baricitinib, remdesivir, and dexamethasone in patients with severe COVID-19 |
title_full | Clinical impact of combination therapy with baricitinib, remdesivir, and dexamethasone in patients with severe COVID-19 |
title_fullStr | Clinical impact of combination therapy with baricitinib, remdesivir, and dexamethasone in patients with severe COVID-19 |
title_full_unstemmed | Clinical impact of combination therapy with baricitinib, remdesivir, and dexamethasone in patients with severe COVID-19 |
title_short | Clinical impact of combination therapy with baricitinib, remdesivir, and dexamethasone in patients with severe COVID-19 |
title_sort | clinical impact of combination therapy with baricitinib, remdesivir, and dexamethasone in patients with severe covid-19 |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8352677/ https://www.ncbi.nlm.nih.gov/pubmed/34413006 http://dx.doi.org/10.1016/j.resinv.2021.07.004 |
work_keys_str_mv | AT izumotakehiro clinicalimpactofcombinationtherapywithbaricitinibremdesiviranddexamethasoneinpatientswithseverecovid19 AT kusenaoyuki clinicalimpactofcombinationtherapywithbaricitinibremdesiviranddexamethasoneinpatientswithseverecovid19 AT awanonobuyasu clinicalimpactofcombinationtherapywithbaricitinibremdesiviranddexamethasoneinpatientswithseverecovid19 AT tonemari clinicalimpactofcombinationtherapywithbaricitinibremdesiviranddexamethasoneinpatientswithseverecovid19 AT sakamotokeita clinicalimpactofcombinationtherapywithbaricitinibremdesiviranddexamethasoneinpatientswithseverecovid19 AT takadakohei clinicalimpactofcombinationtherapywithbaricitinibremdesiviranddexamethasoneinpatientswithseverecovid19 AT mutoyutaka clinicalimpactofcombinationtherapywithbaricitinibremdesiviranddexamethasoneinpatientswithseverecovid19 AT fujimotokazushi clinicalimpactofcombinationtherapywithbaricitinibremdesiviranddexamethasoneinpatientswithseverecovid19 AT saikiayae clinicalimpactofcombinationtherapywithbaricitinibremdesiviranddexamethasoneinpatientswithseverecovid19 AT itoyu clinicalimpactofcombinationtherapywithbaricitinibremdesiviranddexamethasoneinpatientswithseverecovid19 AT matsumotoharuko clinicalimpactofcombinationtherapywithbaricitinibremdesiviranddexamethasoneinpatientswithseverecovid19 AT inomataminoru clinicalimpactofcombinationtherapywithbaricitinibremdesiviranddexamethasoneinpatientswithseverecovid19 |